Molekulare Pathologie benigner gynäkologischer Erkrankungen – ist sie hilfreich bei zukünftigen Therapieentscheidungen?

Zusammenfassung Seit die molekularbiologische Labortechnologie in der Lage ist, sämtliche Gene zu identifizieren und ihre genomischen und nichtgenomischen Aktionen in den einzelnen zellulären Mechanismen zu charakterisieren, erschließt sich ein neues, bisweilen völlig anderes Krankheitsverständnis. Die Kenntnis der exakten Hintergründe einer Erkrankung ermöglicht eine andere Sichtweise und bereitet das Feld für neue ursächliche und individuell maßgeschneiderte Therapieoptionen. Die veränderte Sichtweise und die molekularen Hintergründe benigner gynäkologischer Erkrankungen sollen hier erörtert werden, am Beispiel von Endometriose, Adenomyose und uterinen Tumoren. Abstract Ever since molecular laboratory technology has been able to identify all genes and to characterize their specific genomic and nongenomic modes of action in the individual cellular mechanisms, a completely new understanding of diseases has become possible. Knowledge of the exact background of a disease enables another viewpoint and prepares the field for new causal and individually tailored treatment options. The altered viewpoint and the molecular background of benign gynecological diseases are discussed in this article, particularly with respect to endometriosis, adenomyosis and uterine tumors. Similar content being viewed by others Literatur Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM (2017) Cancer-associated mutations in endometriosis without cancer. N Engl J Med 376(19):1835–1848. https://doi.org/10.1056/NEJMoa1614814 Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kiyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H (2019) Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun 10(1):5785. https://doi.org/10.1038/s41467-019-13708-y Suda K, Nakaoka H, Yoshihara K, Ishiguro T, Tamura R, Mori Y, Yamawaki K, Adachi S, Takahashi T, Kase H, Tanaka K, Yamamoto T, Motoyama T, Inoue I, Enomoto T (2018) Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep 24(7):1777–1789. https://doi.org/10.1016/j.celrep.2018.07.037 Němejcová K, Kenny SL, Laco J, Škapa P, Staněk L, Zikán M, Kleiblová P, McCluggage WG, Dundr P (2015) Atypical polypoid adenomyoma of the uterus: an immunohistochemical and molecular study of 21 cases. Am J Surg Pathol 39(8):1148–1155. https://doi.org/10.1097/PAS.0000000000000428 (PMID: 25828387) Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ (1995) Recurrent rearrangements in the high mobility group protein gene, HMGI‑C, in benign mesenchymal tumours. Nat Genet 10(4):436–444. https://doi.org/10.1038/ng0895-436 Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R, Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334(6053):252–255. https://doi.org/10.1126/science.1208930 Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J (2012) MED12 mutations in uterine fibroids—Their relationship to cytogenetic subgroups. Int J Cancer 131(7):1528–1536. https://doi.org/10.1002/ijc.27424 Markowski DN, Helmke BM, Bartnitzke S, Löning T, Bullerdiek J (2014) Uterine fibroids: do we deal with more than one disease? Int J Gynecol Pathol 33(6):568–572. https://doi.org/10.1097/PGP.0000000000000096 Pérot G, Croce S, Ribeiro A, Lagarde P, Velasco V, Neuville A, Coindre JM, Stoeckle E, Floquet A, MacGrogan G, Chibon F (2012) MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7(6):e40015. https://doi.org/10.1371/journal.pone.0040015 Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, Bullerdiek J, Giancotti V, Van Den Berghe H, Dal Cin P (2000) HMGI‑C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI‑C and HMGI(Y) genes. Lab Invest 80(3):359–369. https://doi.org/10.1038/labinvest.3780040 Kazmierczak B, Dal Cin P, Wanschura S, Borrmann L, Fusco A, Van den Berghe H, Bullerdiek J (1998) HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 23(4):279–285 Hennig Y, Wanschura S, Deichert U, Bartnitzke S, Bullerdiek J (1996) Rearrangements of the high mobility group protein family genes and the molecular genetic origin of uterine leiomyomas and endometrial polyps. Mol Hum Reprod 2(4):277–283. https://doi.org/10.1093/molehr/2.4.277 Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H, Dal Cin P, Fletcher JA, Sklar J (2001) Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci U S A 98(11):6348–6353. https://doi.org/10.1073/pnas.101132598 Nucci MR, Harburger D, Koontz J, Dal Cin P, Sklar J (2007) Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol 31(1):65–70. https://doi.org/10.1097/01.pas.0000213327.86992.d1 McCluggage WG, Connolly L, McBride HA (2010) HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma. Am J Surg Pathol 34(7):1037–1042. https://doi.org/10.1097/PAS.0b013e3181e32a11 Kazmierczak B, Dal Cin P, Wanschura S, Bartnitzke S, Van den Berghe H, Bullerdiek J (1998) Cloning and molecular characterization of part of a new gene fused to HMGIC in mesenchymal tumors. Am J Pathol 152(2):431–435 Nucci MR, Weremowicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ (2001) Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. Genes Chromosomes Cancer 32(2):172–176. https://doi.org/10.1002/gcc.1179 Bulun SE (2009) Endometriosis. N Engl J Med 360(3):268–279. https://doi.org/10.1056/NEJMra0804690 Brosens I, Pijnenborg R, Benagiano G (2013) Defective myometrial spiral artery remodelling as a cause of major obstetrical syndromes in endometriosis and adenomyosis. Placenta 34(2):100–105. https://doi.org/10.1016/j.placenta.2012.11.017 Xue Q, Lin Z, Cheng YH, Huang CC, Marsh E, Yin P, Milad MP, Confino E, Reierstad S, Innes J, Bulun SE (2007) Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 77(4):681–687. https://doi.org/10.1095/biolreprod.107.061804 Cheng YH, Yin P, Xue Q, Yilmaz B, Dawson MI, Bulun SE (2008) Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism. J Clin Endocrinol Metab 93(5):1915–1923. https://doi.org/10.1210/jc.2007-1536 Küpker W, Agic A (2020) Endometriose und Malignität – gibt es ein erhöhtes Risiko? In: Diedrich K, Ludwig M, Griesinger G (Hrsg) Reproduktionsmedizin, 2. Aufl. Springer Berlin, Heidelberg, S 358. https://doi.org/10.1007/978-3-662-57636-6 Brinton LA, Gridley G, Persson I et al (1997) Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176:572–579 Peirce CL, Templeman C, Rossing MA (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13:385–394 (On behalf of the Ovarian Cancer Association Consortium) Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K‑ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70. https://doi.org/10.1038/nm1173 Chapron C, Tosti C, Marcellin L, Bourdon M, Lafay-Pillet MC, Millischer AE, Streuli I, Borghese B, Petraglia F, Santulli P (2017) Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes. Hum Reprod 32(7):1393–1401. https://doi.org/10.1093/humrep/dex088 Bullerdiek J, Rommel B (2018) Factors targeting MED12 to drive tumorigenesis? F1000Res 7:359. https://doi.org/10.12688/f1000research.14227.2 Santamaria X, Mas A, Cervelló I, Taylor H, Simon C (2018) Uterine stem cells: from basic research to advanced cell therapies. Hum Reprod Update 24(6):673–693. https://doi.org/10.1093/humupd/dmy028 Bulun SE, Moravek MB, Yin P, Ono M, 5th Coon JS, Dyson MT, Navarro A, Marsh EE, Zhao H, Maruyama T, Chakravarti D, Kim JJ, Wei JJ (2015) Uterine leiomyoma stem cells: linking progesterone to growth. Semin Reprod Med 33(5):357–365. https://doi.org/10.1055/s-0035-1558451 Holzmann C, Saager C, Mechtersheimer G, Koczan D, Helmke BM, Bullerdiek J (2018) Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with ALK rearrangement and loss of 14q. Oncotarget 9(45):27595–27604. https://doi.org/10.18632/oncotarget.25137 Micci F, Panagopoulos I, Bjerkehagen B, Heim S (2006) Deregulation of HMGA2 in an aggressive angiomyxoma with t(11;12)(q23;q15). Virchows Arch 448(6):838–842. https://doi.org/10.1007/s00428-006-0186-5 Harkness R, McCluggage WG (2021) HMGA2 is a useful marker of vulvovaginal aggressive angiomyxoma but may be positive in other mesenchymal lesions at this site. Int J Gynecol Pathol 40(2):185–189. https://doi.org/10.1097/PGP.0000000000000689 Oliva E, de Leval L, Soslow RA, Herens C (2007) High frequency of JAZF1-JJAZ1 gene fusion in endometrial stromal tumors with smooth muscle differentiation by interphase FISH detection. Am J Surg Pathol 31(8):1277–1284. https://doi.org/10.1097/PAS.0b013e318031f012 Huang HY, Ladanyi M, Soslow RA (2004) Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneity. Am J Surg Pathol 28(2):224–232. https://doi.org/10.1097/00000478-200402000-00010 Chiang S, Ali R, Melnyk N, McAlpine JN, Huntsman DG, Gilks CB, Lee CH, Oliva E (2011) Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol 35(9):1364–1372. https://doi.org/10.1097/PAS.0b013e3182262743 Author information Authors and Affiliations Corresponding author Ethics declarations Interessenkonflikt W. Küpker, J. Aizpurua, R.E. Felberbaum und J. Bullerdiek geben an, dass kein Interessenkonflikt besteht. Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. Additional information Redaktion Thomas Strowitzki, Heidelberg Klaus Diedrich, Lübeck QR-Code scannen & Beitrag online lesen Rights and permissions About this article Cite this article Küpker, W., Aizpurua, J., Felberbaum, R.E. et al. Molekulare Pathologie benigner gynäkologischer Erkrankungen – ist sie hilfreich bei zukünftigen Therapieentscheidungen?. Gynäkologie 55, 409–414 (2022). https://doi.org/10.1007/s00129-022-04951-4 Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s00129-022-04951-4